Company profile
Genprex, Inc.
NASDAQ: GNPX · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenue
EA Score
35DFH 36DQ 32GM —SS 36
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, disclosure history · ↓ return on equity, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$16.2M
Employees
13
as of 2026-08-26
Market cap
$2.0M
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02024
Net income-$16.2M-$16.2M2025
Operating income-$15.5M-$15.5M2025
Total assets$10.2M$10.2M2025
Liabilities$2.2M$2.2M2025
Equity$8.0M$8.0M2025
Revenue trend
FY2021 – FY2024 · USD
FY21
FY22
FY21
FY22
FY22
FY22
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Genprex, Inc.’s revenue?
Genprex, Inc. booked $0 in FY2024 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Psyence Group Inc.——Lifeline Biotechnologies, Inc.——Nu-Med Plus, Inc.23DiMD Companies, Inc.47DTelo Genomics Corp.——Lobe Sciences Ltd.42DNeighbors
Travis →Key facts
CEORyan Confer
SectorHealthcare
IndustryBiotechnology
HeadquartersAustin, TX
ExchangeNASDAQ: GNPX
Employees13
IPO date2018-03-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.